Cited by 122Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchParkinson's Disease Mechanisms and Treatments

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

The substantia nigra and ventral tegmental area in Alzheimer’s disease and Down’s syndrome

Open access

Gibb, W R, Mountjoy, C Q, Mann, D M, Lees, A J·1989·Journal of Neurology, Neurosurgery & Psychiatry

DOI 10.1136/jnnp.52.2.193PMC PMC1032505

Open this paper in CoChat — free account Open PDF

Abstract

Degenerative changes in the substantia nigra and ventral tegmental area were investigated in 104 cases of Alzheimer's disease and 13 cases of Down's syndrome. Frequencies of tangles in three groups of patients with Alzheimer's disease were 86%, 44% and 46% (54% overall) respectively. About half of those with tangles, but no Lewy bodies, had excess nigral cell loss, and 16% had moderate or severe neuronal fallout, but none had a Parkinsonian syndrome. Cases with nigral tangles were younger, tended to have more hippocampal and cortical tangles and plaques, and lower activities of cortical choline acetyltransferase. In most cases of Alzheimer's disease degeneration in nigral and tegmental areas was greater than controls, and tangles were evenly distributed. All the cases of Down's syndrome had tangles in the nigra and eight showed mild cell loss. Mild degenerative changes accompanied by tangles in the substantia nigra and ventral tegmental area are common in Alzheimer's disease, but severe cell loss is rare. When a Parkinsonian syndrome occurs in Alzheimer's disease it is likely to be due to Lewy body pathology.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1136/jnnp.52.2.193

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Progressive Supranuclear Palsy
Steele, J. C. (1964) · Archives of Neurology · doi:10.1001/archneur.1964.00460160003001 · Cited by 1,930
Occurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome
Wisniewski, K. E., Wisniewski, H. M., & Wen, G. Y. (1985) · Annals of Neurology · doi:10.1002/ana.410170310 · Cited by 1,159
Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus ceruleus) in senile dementia
Bondareff, W., Mountjoy, C. Q., & Roth, M. (1982) · Neurology · doi:10.1212/wnl.32.2.164 · Cited by 683
Self-citation
A POST-MORTEM STUDY OF THE CHOLINERGIC AND GABA SYSTEMS IN SENILE DEMENTIA
Rossor, M. N., Garrett, N., Johnson, A. L., Mountjoy, C. Q., Roth, M., & Iversen, L. L. (1982) · Brain · doi:10.1093/brain/105.2.313 · Cited by 460
Self-citation
Cell loss in the locus coeruleus in senile dementia of Alzheimer type
Tomlinson, B. E., Irving, D., & Blessed, G. (1981) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(81)90031-9 · Cited by 453
PARKINSONISM-DEMENTIA COMPLEX, AN ENDEMIC DISEASE ON THE ISLAND OF GUAM
Hirano, A., Kurland, L. T., Krooth, R. S., & Lessell, S. (1961) · Brain · doi:10.1093/brain/84.4.642 · Cited by 419
Alzheimer's disease in Down's syndrome: Clinicopathologic studies
Wisniewski, K. E., Dalton, A. J., McLachlan, D. R. C., Wen, G. Y., & Wisniewski, H. M. (1985) · Neurology · doi:10.1212/wnl.35.7.957 · Cited by 417
ALZHEIMER'S PRESENILE DEMENTIA, SENILE DEMENTIA OF ALZHEIMER TYPE AND DOWN'S SYNDROME IN MIDDLE AGE FORM AN AGE RELATED CONTINUUM OF PATHOLOGICAL CHANGES
Mann, D. M. A., Yates, P. O., & Marcyniuk, B. (1984) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.1984.tb00351.x · Cited by 345
Self-citation
The development of the pathologic changes of Alzheimer's disease and senile dementia in patients with Down's syndrome.
Burger, P. C., & Vogel, F. S. (1973) · PubMed Central · Cited by 342
Nucleus raphe dorsalis in Alzheimer's disease: Neurofibrillary tangles and loss of large neurons
Yamamoto, T., & Hirano, A. (1985) · Annals of Neurology · doi:10.1002/ana.410170608 · Cited by 338

Flagged first, then by citations

Show all 43 references

Sorted by citations

Dopamine and the regulation of cognition and attention
Nieoullon, A. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00011-4 · Cited by 1,131
Pathology of Parkinson’s disease
Jellinger, K. A. (1991) · Molecular and Chemical Neuropathology · doi:10.1007/bf03159935 · Cited by 708
Dopamine neuronal loss contributes to memory and reward dysfunction in a model of Alzheimer’s disease
Nobili, A., Latagliata, E. C., Viscomi, M. T., Cavallucci, V., Cutuli, D., Giacovazzo, G., Krashia, P., Rizzo, F. R., Marino, R., Federici, M., et al. (2017) · Nature Communications · doi:10.1038/ncomms14727 · Cited by 514
Dopaminergic reward system: a short integrative review
Arias-Carrión, Ó., Stamelou, M., Murillo‐Rodríguez, E., Menéndez‐González, M., & Pöppel, E. (2010) · International Archives of Medicine · doi:10.1186/1755-7682-3-24 · Cited by 478
Negative symptoms: the ‘pathology’ of motivation and goal-directed behaviour
Brown, R. G., & Pluck, G. C. (2000) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01626-x · Cited by 297
“Is dopamine involved in Alzheimer's disease?”
Martorana, A., & Koch, G. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00252 · Cited by 276
Dopamine, learning, and reward-seeking behavior
Arias-Carrión, Ó., & Pöppel, E. (2007) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2007-1664 · Cited by 274
Neuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: a meta-analysis
Lyness, S. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00057-x · Cited by 240
Challenges for Alzheimer's Disease Therapy: Insights from Novel Mechanisms Beyond Memory Defects
Frozza, R. L., Lourenco, M. V., & Felice, F. G. D. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00037 · Cited by 213
Topography and collateralization of the dopaminergic projections to motor and lateral prefrontal cortex in owl monkeys
Gaspar, P., Stepniewska, I., & Kaas, J. H. (1992) · The Journal of Comparative Neurology · doi:10.1002/cne.903250102 · Cited by 187
The pathology of the substantia nigra in Alzheimer disease with extrapyramidal signs
Burns, J. M., Galvin, J. E., Roe, C. M., Morris, J. C., & McKeel, D. W. (2005) · Neurology · doi:10.1212/01.wnl.0000158423.05224.7f · Cited by 178
Pathological correlates of extrapyramidal signs in Alzheimer's disease
Liu, Y., Stern, Y., Chun, M. R., Jacobs, D. M., Yau, P. O., & Goldman, J. E. (1997) · Annals of Neurology · doi:10.1002/ana.410410312 · Cited by 129
Turning on the Light Within: Subcortical Nuclei of the Isodentritic Core and their Role in Alzheimer’s Disease Pathogenesis
Theofilas, P., Dunlop, S. R., Heinsen, H., & Grinberg, L. T. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142682 · Cited by 119
Music and Memory in Alzheimer’s Disease and The Potential Underlying Mechanisms
Peck, K. J., Girard, T. A., Russo, F., & Fiocco, A. J. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150998 · Cited by 118
Hallucinations and associated factors in Alzheimer's disease
Gilley, D. W., Whalen, M. E., Wilson, R. S., & Bennett, D. A. (1991) · Journal of Neuropsychiatry · doi:10.1176/jnp.3.4.371 · Cited by 112
Down Syndrome: Advances in Molecular Biology and the Neurosciences
Capone, G. T. (2001) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/00004703-200102000-00007 · Cited by 110
Nilotinib restores memory function by preventing dopaminergic neuron degeneration in a mouse model of Alzheimer’s Disease
La Barbera, L., Vedele, F., Nobili, A., Krashia, P., Spoleti, E., Latagliata, E. C., Cutuli, D., Cauzzi, E., Marino, R., Viscomi, M. T., et al. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2021.102031 · Cited by 98
“deficits in mesocorticolimbic DA signalling (Allard et al., 1990; Costa et al., 2016; Gibb et al., 1989; Joyce et al., 1997; Kemppainen et al., 2003; Koch et al., 2014; Kumar and Patel, 2007; Murray et al., 1995; Rinne et al., 1986a, 1986b; Storga et al., 1996).”
Background
The role of dopaminergic midbrain in Alzheimer’s disease: Translating basic science into clinical practice
D’Amelio, M., Puglisi‐Allegra, S., & Mercuri, N. B. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.01.016 · Cited by 95
SH-SY5Y-derived neurons: a human neuronal model system for investigating TAU sorting and neuronal subtype-specific TAU vulnerability
Bell, M. J., & Zempel, H. (2021) · Reviews in the Neurosciences · doi:10.1515/revneuro-2020-0152 · Cited by 92
Differential Diagnosis of Parkinson’s Disease and the Parkinsonism Plus Syndromes
Stacy, M. A., & Jankovic, J. J. (1992) · Neurologic Clinics · doi:10.1016/s0733-8619(18)30214-7 · Cited by 86
Dementia and Parkinson's Disease
Gibb, W. R. G. (1989) · The British Journal of Psychiatry · doi:10.1192/bjp.154.5.596 · Cited by 87
Self-citation
Nigrostriatal Dysfunction in Familial Alzheimer's Disease-Linked APPswe/PS1ΔE9 Transgenic Mice
Perez, S. E., Lazarov, O., Koprich, J. B., Chen, E., Rodriguez‐Menendez, V., Lipton, J. W., Sisodia, S. S., & Mufson, E. J. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.2773-05.2005 · Cited by 86
Dopamine loss alters the hippocampus-nucleus accumbens synaptic transmission in the Tg2576 mouse model of Alzheimer’s disease
Cordella, A., Krashia, P., Nobili, A., Pignataro, A., La Barbera, L., Viscomi, M. T., Valzania, A., Keller, F., Ammassari-Teule, M., Mercuri, N. B., et al. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.05.006 · Cited by 82
The neuropathology of frontotemporal lobar degeneration with respect to the cytological and biochemical characteristics of tau protein
Taniguchi, S., McDonagh, A. M., Pickering-Brown, S. M., Umeda, Y., Iwatsubo, T., Hasegawa, M., & Mann, D. M. A. (2003) · Neuropathology and Applied Neurobiology · doi:10.1046/j.0305-1846.2003.00481.x · Cited by 75
Self-citation
In vivo human molecular neuroimaging of dopaminergic vulnerability along the Alzheimer’s disease phases
Sala, A., Caminiti, S. P., Presotto, L., Pilotto, A., Liguori, C., Chiaravalloti, A., Garibotto, V., Frisoni, G. B., D’Amelio, M., Paghera, B., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00925-1 · Cited by 67
Clinical and Positron Emission Tomographic Studies in the 'Extrapyramidal Syndrome' of Dementia of the Alzheimer Type
Tyrrell, P. J., Sawle, G. V., Ibanez, V., Bloomfield, P. M., Leenders, K. L., Frackowiak, R. S. J., & Rossor, M. N. (1990) · Archives of Neurology · doi:10.1001/archneur.1990.00530120062011 · Cited by 65
Antidepressant medications in dementia: evidence and potential mechanisms of treatment-resistance
Costello, H., Roiser, J. P., & Howard, R. (2023) · Psychological Medicine · doi:10.1017/s003329172200397x · Cited by 60
Improved Detection of Substantia Nigra Pathology in Alzheimer's Disease
Schneider, J. A., Bienias, J. L., Gilley, D. W., Kvarnberg, D. E., Mufson, E. J., & Bennett, D. A. A. (2002) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215540205000111 · Cited by 57
Cerebrospinal fluid catecholamines in Alzheimer’s disease patients with and without biological disease
Henjum, K., Watne, L. O., Godang, K., Halaas, N. B., Eldholm, R. S., Blennow, K., Zetterberg, H., Saltvedt, I. T., Bollerslev, J., & Knapskog, A. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01901-5 · Cited by 58
Integrating the Roles of Midbrain Dopamine Circuits in Behavior and Neuropsychiatric Disease
Chen, A. P. F., Chen, L., Kim, T. A., & Xiong, Q. (2021) · Biomedicines · doi:10.3390/biomedicines9060647 · Cited by 59
Detection of Lewy Bodies in Trisomy 21 (Down's Syndrome)
Raghavan, R., Khin-Nu, C., Brown, A., Irving, D., Ince, P. G., Day, K. A., Tyrer, S. P., & Perry, R. H. (1993) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100047405 · Cited by 56
Neuropathology of Parkinsonism in Patients with Pure Alzheimer's Disease
Horvath, J. E., Burkhard, P. R., Herrmann, F. R., Bouras, C., & Kövari, E. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131289 · Cited by 48
Pretangle pathology within cholinergic nucleus basalis neurons coincides with neurotrophic and neurotransmitter receptor gene dysregulation during the progression of Alzheimer's disease
Tiernan, C. T., Ginsberg, S. D., He, B., Ward, S., Guillozet-Bongaarts, A. L., Kanaan, N. M., Mufson, E. J., & Counts, S. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.05.021 · Cited by 48
Cannabidiol regulates CB1‐pSTAT3 signaling for neurite outgrowth, prolongs lifespan, and improves health span in Caenorhabditis elegans of Aβ pathology models
Wang, Z., Zheng, P., Xie, Y., Chen, X., Solowij, N., Green, K., Chew, Y. L., & Huang, X. (2021) · The FASEB Journal · doi:10.1096/fj.202002724r · Cited by 48
Selective loss of nigral neurons in Alzheimer's disease: a morphometric study
Uchihara, T., Kondo, H., Kosaka, K., & Tsukagoshi, H. (1992) · Acta Neuropathologica · doi:10.1007/bf00296789 · Cited by 44
Quantitative Proteomic Analysis of Human Substantia Nigra in Alzheimer’s Disease, Huntington’s Disease and Multiple Sclerosis
Chen, S., Lu, F. F., Seeman, P. M., & Liu, F. (2012) · Neurochemical Research · doi:10.1007/s11064-012-0874-2 · Cited by 43
In vivo MRI Structural and PET Metabolic Connectivity Study of Dopamine Pathways in Alzheimer’s Disease
Iaccarino, L., Sala, A., Caminiti, S. P., Presotto, L., Perani, D., & Initiative, F. T. A. D. N. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-190954 · Cited by 40
The VTA dopaminergic system as diagnostic and therapeutical target for Alzheimer's disease
Krashia, P., Spoleti, E., & D’Amelio, M. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1039725 · Cited by 41
Divergence in the metabolome between natural aging and Alzheimer’s disease
Hunsberger, H. C., Greenwood, B. P., Tolstikov, V., Narain, N. R., Kiebish, M. A., & Denny, C. A. (2020) · Scientific Reports · doi:10.1038/s41598-020-68739-z · Cited by 37
The Neurodegenerative Elderly Syndrome (NES) hypothesis: Alzheimer and Parkinson are two faces of the same disease
Caligiore, D., Giocondo, F., & Silvetti, M. (2022) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2022.09.007 · Cited by 40
Dementia with Lewy bodies: a review
Rampello, L., Cerasa, S., Alvano, A., Buttà, Raffaele, R., Vecchio, I., Cavallaro, T., Cimino, E., Incognito, T., & Nicoletti, F. (2004) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2003.11.003 · Cited by 29
Computational Modeling of Catecholamines Dysfunction in Alzheimer’s Disease at Pre-Plaque Stage
Caligiore, D., Silvetti, M., D’Amelio, M., Puglisi‐Allegra, S., & Baldassarre, G. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200276 · Cited by 30
Early derailment of firing properties in CA1 pyramidal cells of the ventral hippocampus in an Alzheimer's disease mouse model
Spoleti, E., Krashia, P., Barbera, L. L., Nobili, A., Lupaşcu, C. A., Giacalone, E., Keller, F., Migliore, M., Renzi, M., & D’Amelio, M. (2021) · Experimental Neurology · doi:10.1016/j.expneurol.2021.113969 · Cited by 29
Neuromelanin in the Human Brain: A Review and Atlas of Pigmented Cells in the Substantia Nigra
Usunoff, K. G., Itzev, D. E., Ovtscharoff, W. A., & Marani, E. (2002) · Archives of Physiology and Biochemistry · doi:10.1076/apab.110.4.257.11827 · Cited by 27
Obsessive-compulsive behaviour and cognitive impairment in a parkinsonian patient after left putaminal lesion.
Daniele, A., Bartolomeo, P., Cassetta, E., Bentivoglio, A. R., Gainotti, G., Albanese, A., & Partolomeo, B. (1997) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.62.3.288 · Cited by 27
A Novel and Selective Dopamine Transporter Inhibitor, (S)-MK-26, Promotes Hippocampal Synaptic Plasticity and Restores Effort-Related Motivational Dysfunctions
Kouhnavardi, S., Ecevitoglu, A., Dragačević, V., Sanna, F., Arias‐Sandoval, E., Kalaba, P., Kirchhofer, M., Lubec, J., Niello, M., Holy, M., et al. (2022) · Biomolecules · doi:10.3390/biom12070881 · Cited by 24
Selective loss of nigral neurons in Pick's disease: a morphometric study
Uchihara, T., Tsuchiya, K., & Kosaka, K. (1990) · Acta Neuropathologica · doi:10.1007/bf00334504 · Cited by 24
Alzheimer-type pathology in melanin-bleached sections of substantia nigra
Uchihara, T., Kondo, H., Ikeda, K., & Kosaka, K. (1995) · Journal of Neurology · doi:10.1007/bf00867417 · Cited by 23
The neostriatum and nucleus accumbens in parkinsonism-dementia complex of Guam: a pathological comparison with Alzheimer's disease and progressive supranuclear palsy
Oyanagi, K., Makifuchi, T., Ohtoh, T., Chen, K.-M., Gajdusek, D. C., Chase, T. N., & Ikuta, F. (1994) · Acta Neuropathologica · doi:10.1007/bf00294504 · Cited by 23
Loss of non-phosphorylated neurofilament immunoreactivity, with preservation of tyrosine hydroxylase, in surviving substantia nigra neurons in Parkinson's disease.
Gai, W., Vickers, J. C., Blumbergs, P. C., & Blessing, W. W. (1994) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.9.1039 · Cited by 23
Neurological Soft Signs in Nursing Home Residents with Alzheimer's Disease
Seidl, U., Thomann, P. A., & Schröder, J. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1159 · Cited by 22
EXTRAPYRAMIDAL SIGNS IN DEMENTIA OF ALZHEIMER TYPE
Tyrrell, P. J., & Rossor, M. N. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91580-8 · Cited by 22
Extrapyramidal features in advanced Down's syndrome: clinical evaluation and family history.
Vieregge, P., Ziemens, G., Freudenberg, M. A., Piosinski, A., Muysers, A., & Schulze, B. W. (1991) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.54.1.34 · Cited by 21
Gray matter volume covariance networks associated with social networks in older adults
Blumen, H. M., & Verghese, J. (2018) · Social Neuroscience · doi:10.1080/17470919.2018.1535999 · Cited by 20
Autophagy status as a gateway for stress-induced catecholamine interplay in neurodegeneration
Fornai, F., & Puglisi‐Allegra, S. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.01.015 · Cited by 20
Rodent Models of Alzheimer’s Disease: Past Misconceptions and Future Prospects
Collins, H. M., & Greenfield, S. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116222 · Cited by 21
Neuropathology of the Brainstem to Mechanistically Understand and to Treat Alzheimer’s Disease
Patthy, Á., Murai, J., Hanics, J., Pintér, A., Zahola, P., Hökfelt, T. G. M., Harkany, T., & Alpár, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081555 · Cited by 17
Allopregnanolone enhances the neurogenesis of midbrain dopaminergic neurons in APPswe/PSEN1 mice
Zhang, P., Xie, M. Q., Ding, Y., Liao, M., Qi, S. S., Chen, S. X., Gu, Q., Zhou, P., & Sun, C. Y. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.01.019 · Cited by 18
Role of the dorsomedial nucleus of the thalamus in Alzheimer's disease.
Paskavitz, J., Lippa, C. F., Hamos, J. E., Pulaski-Salo, D., & Drachman, D. A. (1995) · PubMed · Cited by 18
Dopaminergic deficits along the spectrum of Alzheimer’s disease
Pilotto, A., Galli, A., Sala, A., Caminiti, S. P., Presotto, L., Liguori, C., Mercuri, N. B., Premi, E., Garibotto, V., Frisoni, G. B., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-02913-5 · Cited by 17
Is the pattern of nerve cell loss in ageing and Alzheimer's disease a real, or only an apparent, selectivity?
Mann, D. M. A. (1991) · Neurobiology of Aging · doi:10.1016/0197-4580(91)90015-c · Cited by 17
Self-citation
The effect of Lewy body (co-)pathology on the clinical and imaging phenotype of amnestic patients
Silva‐Rodríguez, J., Labrador‐Espinosa, M. Á., Zhang, L., Castro‐Labrador, S., López‐González, F. J., Moscoso, A., Sánchez‐Juan, P., Schöll, M., & Grothe, M. J. (2025) · Brain · doi:10.1093/brain/awaf037 · Cited by 16
Distinct FP-CIT PET patterns of Alzheimer’s disease with parkinsonism and dementia with Lewy bodies
Chung, S. J., Lee, Y. H., Yoo, H. S., Sohn, Y. H., Ye, B. S., Cha, J., & Lee, P. H. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04315-6 · Cited by 16
Cognitive Impairment in Alzheimer’s and Metabolic Diseases: A Catecholaminergic Hypothesis
Guzmán-Ramos, K. R., Osorio‐Gómez, D., & Bermúdez‐Rattoni, F. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.05.031 · Cited by 15
Down's syndrome and Parkinson's disease.
Hestnes, A., Daniel, S. E., Lees, A. J., & Brun, A. (1997) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.62.3.289 · Cited by 14
Self-citation
Molecular mechanisms highlighting the potential role of COVID-19 in the development of neurodegenerative diseases
Rahmani, B., Ghashghaei, E., Zendehdel, M., Baghbanzadeh, A., & Khodadadi, M. (2022) · Physiology International · doi:10.1556/2060.2022.00019 · Cited by 13
Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early‐onset Alzheimer's disease
Dekker, A. D., Vermeiren, Y., Carmona‐Iragui, M., Benejam, B., Videla, L., Gelpí, E., Aerts, T., Dam, D. V., Fernández, S., Lleó, A., et al. (2017) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.11.001 · Cited by 15
Localisation and association of pathomorphological changes at the brainstem in Alzheimer's disease
Giess, R., & Schlote, W. (1995) · Mechanisms of Ageing and Development · doi:10.1016/0047-6374(95)01657-0 · Cited by 13
Dopamine System Dysfunction in Alzheimer's Disease
Moreira, I. P., Vieira‐Coelho, M. A., & Guimarães, J. (2025) · Psychogeriatrics · doi:10.1111/psyg.70097 · Cited by 12
Automated MRI Segmentation of Brainstem Nuclei Critical to Consciousness
Olchanyi, M., Augustinack, J. C., Haynes, R. L., Lewis, L. D., Cicero, N. G., Li, J., Destrieux, C., Folkerth, R. D., Kinney, H. C., Fischl, B. R., et al. (2025) · Human Brain Mapping · doi:10.1002/hbm.70357 · Cited by 12
No correlation between nigral degeneration and striatal plaques in Alzheimer's disease
Love, S., Wilcock, G., & Matthews, S. M. (1996) · Acta Neuropathologica · doi:10.1007/s004010050447 · Cited by 12
Extracts of Sideritis scardica and Clinopodium vulgare Alleviate Cognitive Impairments in Scopolamine-Induced Rat Dementia
Lazarova, M. I., Tsvetanova, E. R., Georgieva, A. P., Stefanova, M. O., Uzunova, D. N., Denev, P. N., Vassileva, V., & Tasheva, K. N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031840 · Cited by 11
Effect of Combined Electroacupuncture and Selegiline Treatment in Alzheimer’s Disease: An Animal Model
Cai, M., & Yang, E. J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.606480 · Cited by 11
Beyond the brain: early autonomic dysfunction in Alzheimer’s disease
Nanclares, C., Colmena, I., Muñoz-Montero, A., Baraibar, A. M., de Pascual, R., Wojnicz, A., Ruíz‐Nuño, A., Garcı́a, A. G., Gironda-Martínez, A., & Gandı́a, L. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-02042-8 · Cited by 10
Coupling CZE, Liquid‐Phase Ion Mobility, to MS/MS for Quantitative Top‐Down Proteomics: Revealing Significant Proteoform Differences Between Healthy and Alzheimer's Disease Brains
Askarani, M. F., Fang, F., Counts, S., & Sun, L. (2025) · PROTEOMICS · doi:10.1002/pmic.70041 · Cited by 10
Functional Correlates of Striatal Dopamine Transporter Cerebrospinal Fluid Levels in Alzheimer’s Disease: A Preliminary 18F-FDG PET/CT Study
Camedda, R., Bonomi, C. G., Donna, M. G. D., & Chiaravalloti, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24010751 · Cited by 10
Clinical parkinsonism in dementia patients with substantia nigra Lewy bodies
Ala, T. A., Yang, K.-H., Sung, J. H., & Frey, W. H. (1999) · Journal of Neural Transmission · doi:10.1007/s007020050140 · Cited by 10
Cortical Lewy Body Dementia
Gibb, W. R. G. (1990) · Behavioural Neurology · doi:10.1155/1990/235953 · Cited by 9
Self-citation
Neurotransmitter Changes in Alzheimer’s Disease
Halliday, G. M., & Cullen, K. M. (1995) · Advances in behavioral biology · doi:10.1007/978-1-4615-1853-2_12 · Cited by 8
Neurotransmitter Systems in Hippocampus and Prelimbic Cortex, Dopamine-Acetylcholine Interactions in Hippocampus, and Memory in the Rat
Brito, G. N. O. (1992) · Birkhäuser Boston eBooks · doi:10.1007/978-1-4615-9843-5_10 · Cited by 8
Neuropathology of Alzheimer’s disease in Down syndrome
Mann, D. M. A. (2018) · CRC Press eBooks · doi:10.1201/9781315376875-2 · Cited by 6
Self-citation
Lack of Association Between Down Syndrome and Polymorphisms in Dopamine Receptor D4 and Serotonin Transporter Genes
Bhowmik, A. D., Dutta, S., Sinha, S., Chattopadhyay, A., & Mukhopadhyay, K. (2008) · Neurochemical Research · doi:10.1007/s11064-007-9581-9 · Cited by 6
The First Confirmed Case of Down Syndrome with Dementia with Lewy Bodies
Prasher, V. P., Airuehia, E., & Carey, M. (2010) · Journal of Applied Research in Intellectual Disabilities · doi:10.1111/j.1468-3148.2009.00526.x · Cited by 6
Catecholaminergic nucleus integrity and Alzheimer's pathology, symptoms, and progression
David, M., Kolanko, M., Parker, T. D., Nilforooshan, R., Zimmerman, K. A., Olivares, C. B., Hoang, K., Brandt, J., Triantafyllou, C., Lally, P., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70749 · Cited by 7
Yoga for Neurodegenerative Disorders: Therapeutic Effects, Mechanisms, and Applications in Alzheimer’s and Parkinson’s Disease
Zoila, F., de Stefano, M. I., Sgobbio, A., Panaro, M. A., Maffione, A. B., Antonucci, L., Benameur, T., Massaro, M., Gaban, S. V. F., Filannino, F. M., et al. (2025) · Sports · doi:10.3390/sports13120458 · Cited by 6
Levodopa-Responsive Early-Onset Parkinsonism in Down Syndrome
Padmini, P., Hickey, F. J., Patel, L., & Sannar, E. M. (2018) · Case Reports in Neurological Medicine · doi:10.1155/2018/2314791 · Cited by 5
Parkinsonian features in advanced Down’s syndrome
Vieregge, P., Ziemens, G., Piosinski, A., Freudenberg, M. A., & Kömpf, D. (1991) · Springer eBooks · doi:10.1007/978-3-7091-9135-4_19 · Cited by 5
An autopsied case of Down syndrome with Alzheimer pathology and α‐synuclein immunoreactivity
Marui, W., Iseki, E., Kosaka, K., Kato, M., Adachi, Y., & Uéda, K. (1999) · Neuropathology · doi:10.1046/j.1440-1789.1999.00265.x · Cited by 5
Cognitive effects of dopaminergic treatment in Alzheimer's disease: Systematic review and meta‐analysis
Olivares, C. B., David, M., Obeso, M. E., Giovane, M. D., Reeves, S., & Malhotra, P. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70142 · Cited by 4
In vivo human molecular neuroimaging of dopaminergic vulnerability along the Alzheimer’s disease phasesPreprint
Perani, D., Sala, A., Caminiti, S. P., Presotto, L., Pilotto, A., Liguori, C., Chiaravalloti, A., Garibotto, V., Frisoni, G. B., D’Amelio, M., et al. (2021) · doi:10.21203/rs.3.rs-212818/v1 · Cited by 4
Different patterns of β-amyloid deposition in patients with Alzheimer's disease according to the presence of mild parkinsonism
Chung, S. J., Lee, S., Yoo, H. S., Baik, K., Lee, H. S., Jung, J. H., Choi, Y., Hong, J., Kim, Y. J., Ye, B. S., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.01.022 · Cited by 3
Parkinsonism-Plus Syndromes and Secondary Parkinsonian Disorders
Fahn, S., Jankovic, J. J., Hallett, M., & Jenner, P. G. (2007) · Elsevier eBooks · doi:10.1016/b978-0-443-07941-2.50013-9 · Cited by 3
PARKINSONISM AND DOWN SYNDROME
Sturman, S. G., & Williams, A. C. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91581-x · Cited by 3
Age-Related Changes in Subcortical Nuclei that Project to the Cerebral Cortex
Kemper, T. L. (1999) · Cerebral cortex · doi:10.1007/978-1-4615-4885-0_10 · Cited by 3
Alzheimer's disease traits in Parkinson's disease without α‐synuclein seeding
Gomes, B. F., Farris, C. M., Ma, Y., Concha‐Marambio, L., Nilsson, J., Forsberg, K., Lebovitz, R. M., Andréasson, U., Blennow, K., Zetterberg, H., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70284 · Cited by 2
Dopaminergic Nerve Terminal Imaging Across the Spectrum of Aging, Idiopathic Rapid Eye Movement (REM) Sleep Behavior Disorder, Parkinsonism and Dementia
Ota, Y., Kanel, P., Barr, J., Spears, C. C., & Bohnen, N. I. (2023) · Springer eBooks · doi:10.1007/978-3-031-35098-6_7 · Cited by 2
Atypical parkinsonism, parkinsonism-plus syndromes, and secondary parkinsonian disorders
Fahn, S., Jankovic, J. J., & Hallett, M. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-2369-4.00009-3 · Cited by 2
Frequency of mixed neuropathologies in individuals with Down syndrome with and without Alzheimer's dementia
Aguilar, L. F., Zaikos, T. D., Rivera, I., Wright, S. T., Lou, J., Gawronski, B., Gonzalez, L., Berry, J. V., Rouanet, J. P., Edwards, N. C., et al. (2026) · Acta Neuropathologica · doi:10.1007/s00401-026-03028-z · Cited by 1
Age-related changes in the catecholaminergic neurons of the mesopontine tegmentum in the rat
Itzev, D. E., Ovtscharoff, W. A., Marani, E., & Usunoff, K. G. (2007) · Biomedical Reviews · doi:10.14748/bmr.v18.67 · Cited by 1
Brain stem lesions in Pick's disease
Teruyuki, O. D. A. (1991) · Okayama Igakkai Zasshi (Journal of Okayama Medical Association) · doi:10.4044/joma1947.103.11-12_1237 · Cited by 1

Authors: Gibb, W. R., Mountjoy, C. Q., Mann, D. M., & Lees, A. J.
ORCID: Gibb, W R
Mann, D M
Lees, A J
Venue: Journal of Neurology, Neurosurgery & Psychiatry
Publisher: BMJ
Published: 1989-02-01
Volume: 52
Issue: 2
Pages: 193-200
ISSN: 0022-3050 (ISSN-L)
DOI: 10.1136/jnnp.52.2.193
PMC: PMC1032505
OpenAlex: W2015429211
Cited by: 122
References: 43
Citations by year: 2026: 3 · 2025: 10 · 2024: 4 · 2023: 14 · 2022: 7 · 2021: 10 · 2020: 4 · 2019: 2 · 2018: 7 · 2017: 2 · 2016: 1 · 2015: 2 · 2014: 2 · 2012: 1
FWCI: 4.65
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Neurology Neurosurgery & Psychiatry (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
UCL Discovery (University College London) (submittedVersion)
HighWire Press Open Archive (submittedVersion)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Keywords: substantia nigra, ventral tegmental area, Alzheimer's disease, Down syndrome, neurofibrillary tangles, Lewy bodies, parkinsonism, choline acetyltransferase
MeSH terms: Adult, Aged, Aged, 80 and over, Alzheimer Disease, Cell Count, Inclusion Bodies, Cerebral Cortex, Down Syndrome, Female, Hippocampus, Humans, Male, Melanins, Middle Aged, Nerve Degeneration, Neurofibrils, Neurons, Substantia Nigra, Tegmentum Mesencephali

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The substantia nigra and ventral tegmental area in Alzheimer’s disease and Down’s syndrome

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks